AbbVie, Parkinson's disease and Phase III
AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), ACADIA ...
AbbVie (NYSE: ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V) in ...
Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...
After spinning off from Abbott Labs in 2013, biopharmaceutical giant AbbVie had to establish its own culture. Here's how the ...
AbbVie Inc. closed $6.44 short of its 52-week high ($199.95), which the company achieved on September 3rd.
In the latest market close, AbbVie (ABBV) reached $191.26, with a -1.16% movement compared to the previous day. The stock's performance was behind the S&P 500's daily loss of 0.19%. Meanwhile, the Dow ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback